Cramer et al. have discussed that exposure to a PD-1 inhibitor prolongs survival in recurrent/metastatic HNSCC, which includes OSCC, as proven by randomized phase III trials [101]. Here, PDCD1 is linked to head and neck squamous cell carcinoma.